A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 1,001–1,018 of 1,018
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
“properties of solubility and intestinal permeability [17].”
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
Zhang, T., Heimbach, T., Lin, W., Zhang, J., & He, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24373 · Cited by 56
Michaelsen, M. H., Wasan, K. M., Sivak, O., Müllertz, A., & Rades, T. (2016) · The AAPS Journal · doi:10.1208/s12248-015-9832-7 · Cited by 55
“The physico-chemical properties of highly lipophilic compounds often result in poor and variable bioavailability (1,2).”
Siqueira Jørgensen, S. D., Al Sawaf, M., Graeser, K., Mu, H., Müllertz, A., & Rades, T. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.12.014 · Cited by 51
Amidon, K. S., Langguth, P., Lennernäs, H., Yu, L., & Amidon, G. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.109 · Cited by 44
Self-citationMargolskee, A., Darwich, A. S., Pepin, X., Pathak, S. M., Bolger, M. B., Aarons, L., Rostami-Hodjegan, A., Angstenberger, J., Graf, F., Laplanche, L., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.09.027 · Cited by 43
Self-citationHansmann, S., Darwich, A., Margolskee, A., Aarons, L., & Dressman, J. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12618 · Cited by 38
“To examine the influence of different combinations of solubility and permeability limitations on the fraction absorbed, APIs were selected from each of the four BCS classes.([17]) In addition, API selection was based on the availability of data of good enough quality and reproducibility to enable successful implementa…”
BackgroundMethodInfluentialMalm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00278 · Cited by 36
Self-citationRole of Drug Delivery System in Improving the Bioavailability of Resveratrol
Saleem, Z., Rehman, K., & Hamid Akash, M. S. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220705113514 · Cited by 34
Nanoformulations of Albendazole As Effective Anticancer and Antiparasite Agents
Movahedi, F., Li, L., Gu, W., & Xu, Z. P. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0102 · Cited by 34
Advancing product quality: a summary of the second FDA/PQRI conference
Yu, L. X., Akseli, I., Allen, B., Amidon, G., Bizjak, T. G., Boam, A., Caulk, M., Doleski, D., Famulare, J., Fisher, A. C., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9874-5 · Cited by 33
“The BCS is a scientific and risk-based framework for classifying a drug substance based on its aqueous solubility and intestinal permeability (11).”
BackgroundSelf-citationMendes, C., Buttchevitz, A., Kruger, J. H., Kratz, J. M., Simões, C. M. O., de Oliveira Benedet, P., Oliveira, P. R., & Silva, M. A. S. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.015 · Cited by 31
Wollmer, E., Karkossa, F., Freerks, L., Hetberg, A.-E., Neal, G., Porter, J., Whitaker, M. J., Margetson, D., & Klein, S. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02912-x · Cited by 30
“It should be noted that the current BCS refers to adult administration and that a pediatric BCS has not yet been established (10).”
BackgroundGadalla, H. H., Mohammed, F. A., El-Sayed, A. M., & Soliman, G. M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119070 · Cited by 27
Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments
Johannsson, G., Skrtic, S., Lennernäs, H., Quinkler, M., & Stewart, P. M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.925865 · Cited by 21
Self-citationKesisoglou, F. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-013-0030-6 · Cited by 20
“In many of these later cases, the Biopharmaceutics Classification System (BCS) (2) or variations of that are used”
Molecular Biosimilarity—An AI-Driven Paradigm Shift
Niazi, S. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810690 · Cited by 18
“When generic chemical drugs arrived in 1984 [48], they were only available for branded drugs that had undergone extensive testing for safety and efficacy.”
BackgroundCook, J. (2015) · Dissolution Technologies · doi:10.14227/dt220215p6 · Cited by 8
“Amidon and coworkers (1) introduced the biopharmaceutic classification system (BCS) in 1995.”
Background
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.